Related Experiment Video

Updated: Jul 13, 2026

Extended 78% Hepatectomy in a Mouse Surgical Model
05:25

Extended 78% Hepatectomy in a Mouse Surgical Model

Published on: May 24, 2024

[Liver cirrhosis and therapy issues]

V P Shypulin

    Likars'Ka Sprava
    |August 9, 2007
    PubMed

    Insights

    Child-Pugh criteria effectively assess liver protection therapy in cirrhosis patients. Ursodeoxycholic acid improves clinical signs, reduces liver cell damage, and enhances survival rates over two years.

    Area of Science:

    • Hepatology
    • Internal Medicine
    • Pharmacology

    Background:

    • Liver cirrhosis is a severe condition with limited treatment options.
    • Child-Pugh criteria are established for assessing liver function and prognosis.
    • Protective liver therapies aim to improve clinical outcomes and patient survival.

    Purpose of the Study:

    • To evaluate the efficacy of ursodeoxycholic acid as a protective therapy for liver cirrhosis.
    • To assess the impact of this therapy on clinical signs and cellular processes in the liver.
    • To determine the effect of ursodeoxycholic acid on patient survival rates.

    Main Methods:

    • Utilized Child-Pugh criteria as a key metric for evaluating therapeutic effectiveness.
    • Administered ursodeoxycholic acid as a protective therapy to patients with liver cirrhosis.
    • Monitored main clinical signs of liver cirrhosis and hepatocyte processes.

    Main Results:

    • Ursodeoxycholic acid demonstrated a positive effect on the main clinical signs of liver cirrhosis.
    • The therapy led to a decrease in dystrophic processes within hepatocytes.
    • Reparative processes in hepatocytes were enhanced, alongside an increased two-year survival rate.

    Conclusions:

    • Ursodeoxycholic acid is an effective protective therapy for patients with liver cirrhosis.
    • The treatment improves liver function, promotes cellular repair, and increases patient longevity.
    • Child-Pugh criteria reliably indicate the positive impact of ursodeoxycholic acid therapy.

    Related Concept Videos

    Cirrhosis I: Introduction01:23

    Cirrhosis I: Introduction

    Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
    Cirrhosis II: Pathophysiology01:24

    Cirrhosis II: Pathophysiology

    Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
    Esophageal Varices-II: Clinical Features and Management01:28

    Esophageal Varices-II: Clinical Features and Management

    Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
    In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
    Diseases of the Liver and Gallbladder01:26

    Diseases of the Liver and Gallbladder

    Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
    Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...